Use local knee injection when: - You have a specific, localized injury (torn ACL, MCL sprain, patellar tendinopathy, meniscus tear) - Pain concentrates in one area of the knee - You can identify the approximate location of the damaged structure Use systemic injection when: - You have diffuse knee pain without a clear source - Multiple structures are involved (post-surgical, advanced osteoarthritis) - You are stacking BPC-157 with TB-500 for broader systemic repair - You cannot tolerate injections near the knee Split protocol: Some users inject 60-70% of their daily dose locally near the knee and the remaining 30-40% subcutaneously in the abdomen
Presence of coronary endothelial dysfunction, coronary vasospasm, and adenosine-mediated vasodilatory disorders in patients with ischemia and nonobstructive coronary arteries
Three phases of detoxification:[ref] Phase I (bioactivation transformation) involves breaking apart large toxins and converting them into polar molecules
There is no physical downtime associated with BPC-157 Peptide Therapy, and normal daily activities can usually be continued without interruption
Support for joint, tendon, and soft tissue recovery
Patient advocacy efforts to increase patient access and insurance coverage are critical
